Annual CFO
-$175.60 M
+$47.20 M+21.18%
December 31, 2024
Summary
- As of March 12, 2025, SWTX annual cash flow from operations is -$175.60 million, with the most recent change of +$47.20 million (+21.18%) on December 31, 2024.
- During the last 3 years, SWTX annual CFO has fallen by -$47.72 million (-37.32%).
- SWTX annual CFO is now -1139.58% below its all-time high of -$14.17 million, reached on December 31, 2018.
Performance
SWTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$29.50 M
-$4.12 M-16.24%
December 31, 2024
Summary
- As of March 12, 2025, SWTX quarterly cash flow from operations is -$29.50 million, with the most recent change of -$4.12 million (-16.24%) on December 31, 2024.
- Over the past year, SWTX quarterly CFO has increased by +$12.29 million (+29.41%).
- SWTX quarterly CFO is now -295.81% below its all-time high of $15.07 million, reached on December 31, 2020.
Performance
SWTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$175.60 M
+$33.20 M+15.90%
December 31, 2024
Summary
- As of March 12, 2025, SWTX TTM cash flow from operations is -$175.60 million, with the most recent change of +$33.20 million (+15.90%) on December 31, 2024.
- Over the past year, SWTX TTM CFO has increased by +$58.29 million (+24.92%).
- SWTX TTM CFO is now -2346.69% below its all-time high of -$7.18 million, reached on March 31, 2019.
Performance
SWTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SWTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.2% | +29.4% | +24.9% |
| 3 y3 years | -37.3% | +29.4% | +24.9% |
| 5 y5 years | -270.1% | +29.4% | +24.9% |
SWTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -37.3% | +21.2% | -50.5% | +62.6% | -37.3% | +26.8% |
| 5 y | 5-year | -445.5% | +21.2% | -295.8% | +62.6% | -445.5% | +26.8% |
| alltime | all time | -1139.6% | +21.2% | -295.8% | +62.6% | -2346.7% | +26.8% |
SpringWorks Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$175.60 M(-21.2%) | -$29.50 M(+16.2%) | -$175.60 M(-15.9%) |
| Sep 2024 | - | -$25.38 M(-39.3%) | -$208.80 M(-10.7%) |
| Jun 2024 | - | -$41.79 M(-47.1%) | -$233.89 M(-2.5%) |
| Mar 2024 | - | -$78.93 M(+25.9%) | -$239.91 M(+7.7%) |
| Dec 2023 | -$222.79 M(+37.9%) | -$62.70 M(+24.3%) | -$222.79 M(+4.0%) |
| Sep 2023 | - | -$50.46 M(+5.5%) | -$214.29 M(+16.8%) |
| Jun 2023 | - | -$47.81 M(-22.7%) | -$183.43 M(+5.0%) |
| Mar 2023 | - | -$61.82 M(+14.1%) | -$174.69 M(+8.1%) |
| Dec 2022 | -$161.56 M(+26.3%) | -$54.20 M(+176.5%) | -$161.56 M(+5.1%) |
| Sep 2022 | - | -$19.60 M(-49.8%) | -$153.68 M(-4.5%) |
| Jun 2022 | - | -$39.07 M(-19.8%) | -$161.00 M(+3.6%) |
| Mar 2022 | - | -$48.69 M(+5.1%) | -$155.46 M(+21.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$127.88 M(+297.2%) | -$46.32 M(+72.0%) | -$127.88 M(+92.3%) |
| Sep 2021 | - | -$26.93 M(-19.7%) | -$66.50 M(+22.5%) |
| Jun 2021 | - | -$33.53 M(+58.9%) | -$54.27 M(+47.1%) |
| Mar 2021 | - | -$21.10 M(-240.1%) | -$36.90 M(+14.6%) |
| Dec 2020 | -$32.19 M(-32.1%) | $15.07 M(-202.5%) | -$32.19 M(-49.2%) |
| Sep 2020 | - | -$14.70 M(-9.0%) | -$63.32 M(+6.0%) |
| Jun 2020 | - | -$16.16 M(-1.5%) | -$59.73 M(+5.4%) |
| Mar 2020 | - | -$16.40 M(+2.1%) | -$56.66 M(+19.4%) |
| Dec 2019 | -$47.44 M(+234.9%) | -$16.06 M(+44.5%) | -$47.44 M(+51.2%) |
| Sep 2019 | - | -$11.11 M(-15.1%) | -$31.38 M(+54.8%) |
| Jun 2019 | - | -$13.09 M(+82.4%) | -$20.27 M(+182.4%) |
| Mar 2019 | - | -$7.18 M | -$7.18 M |
| Dec 2018 | -$14.17 M | - | - |
FAQ
- What is SpringWorks Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics annual CFO year-on-year change?
- What is SpringWorks Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics quarterly CFO year-on-year change?
- What is SpringWorks Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics TTM CFO year-on-year change?
What is SpringWorks Therapeutics annual cash flow from operations?
The current annual CFO of SWTX is -$175.60 M
What is the all time high annual CFO for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high annual cash flow from operations is -$14.17 M
What is SpringWorks Therapeutics annual CFO year-on-year change?
Over the past year, SWTX annual cash flow from operations has changed by +$47.20 M (+21.18%)
What is SpringWorks Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SWTX is -$29.50 M
What is the all time high quarterly CFO for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high quarterly cash flow from operations is $15.07 M
What is SpringWorks Therapeutics quarterly CFO year-on-year change?
Over the past year, SWTX quarterly cash flow from operations has changed by +$12.29 M (+29.41%)
What is SpringWorks Therapeutics TTM cash flow from operations?
The current TTM CFO of SWTX is -$175.60 M
What is the all time high TTM CFO for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high TTM cash flow from operations is -$7.18 M
What is SpringWorks Therapeutics TTM CFO year-on-year change?
Over the past year, SWTX TTM cash flow from operations has changed by +$58.29 M (+24.92%)